Zobrazeno 1 - 10
of 27
pro vyhledávání: '"J.G.M. Segalla"'
Autor:
Carlos H. Barrios, Gustavo Werutsky, Ruffo Freitas-Junior, Gilson Delgado, Jeovany Martínez-Mesa, Susanne Crocamo, Yeni Verônica do Nascimento, Lissandra Dal Lago, G. Borges, José Bines, Brigitte Marie H.R. Adam Van Eyll, Joao Soares Nunes, Daniel Luiz Gimenes, Andrea J.S. Gomes, J.G.M. Segalla, Daniela Dornelles Rosa, Fernando Chalu Pacheco, Sergio Daniel Simon, Sergio J Azevedo, Facundo Zaffaroni, Geraldo Silva Queiroz
Publikováno v:
The Breast. 44:113-119
Objective To describe stage I-III breast cancer (BC) molecular subtypes and outcomes among a cohort of patients from Brazil. Methods AMAZONA study is a retrospective cohort conducted from June 2008 to January 2009 including women of at least 18 years
Autor:
Roberto Torres, P López-Álvarez, Carlos Sampaio, Carlos Barrios, E Villar, Eva Carrasco, A. Lluch, L Pérez-Michel, J.G.M. Segalla, S. Reyes, JA Garcia-Saenz, J. Cárdenas, Maria Jose Godes, M. Ramos, J Castellanos, A. Ruiz, M. J. Escudero, E Martínez de Dueñas, Lourdes Calvo, J Moncayo, J. M. Baena, Manuel Ruiz-Borrego, J. Vinholes, L Torrecillas, Susana Bezares, M. Martin, Henry L. Gomez, Agust Barnadas, M. A. Seguí, Antonio Llombart, Gilberto Luiz da Silva Amorim, J. Bines, Álvaro Rodríguez-Lescure, M Rodríguez de la Borbolla, Antonio Antón, J de la Haba, B Cardemil, E Garcia
Publikováno v:
Cancer Research. 79:GS2-04
Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts). CIBOMA/2004-01_GEICAM/2003-11 is a multinational, randomized phase III trial exploring adj
Autor:
Fauze Maluf-Filho, João Nunes de Matos Neto, Nils Gunnar Skare, Hezio Jadir Fernandes Júnior, Maria Nunes Álvares, J.G.M. Segalla, Bruno de Araújo Lima França, Ismael Dale Cotrim Guerreiro da Silva, Carlos J C Andrade, Auro Del Giglio, Giuliano Santos Borges, Gustavo Girotto, Nora Manoukian Forones, Sergio J Azevedo, Nicolas Lazaretti, Daniel Grabarz, Gilberto de Castro Junior, Celio Kussumoto, José Luiz Pedrini
Publikováno v:
European journal of cancer (Oxford, England : 1990). 88
Purpose Chemoradiotherapy is the standard treatment for patients with inoperable locally advanced oesophageal cancer. We sought to assess the safety and efficacy of chemoradiation combined with nimotuzumab, a humanised antibody directed against epide
Autor:
Luciano de Souza Viana, Tomoya Yokota, José Dinis, Manuel Chaves-Conde, Chaitali Singh Nangia, Jan B. Vermorken, J.G.M. Segalla, Robert I. Haddad, Ilya Romanov, Jean Bourhis, Jose Manuel Trigo Perez, Kevin J. Harrington, Irina A. Vasilevskaya, E. Ehrnrooth, Amanda Psyrri, Neil W. Gibson, Bushi Wang, Ezra E.W. Cohen, Makoto Tahara, Barbara Burtness
Publikováno v:
Journal of Clinical Oncology. 35:6001-6001
6001 Background: Locally advanced HNSCC is treated curatively, but recurrence is common. In HNSCC, EGFR is richly expressed and EGFR inhibition is validated treatment (tx); the ErbB family blocker afatinib (A) showed efficacy in recurrent/metastatic
Autor:
Miguel Gil, Marc Espié, Frederico Costa, José Baselga, Bernardo Garicochea, Antonio Llombart, Brigitte M. Van Eyll, Begoña Bermejo, Josefa Morales, Sunhee Kwon Ro, Henri Roché, Hélio Pinczowski, J.G.M. Segalla, Patricia Gomez, Miguel Angel Climent Duran, Auro Del Giglio, Clarissa Mathias, Eva Ciruelos, Belén Ojeda, Paulo M. Hoff, Ronaldo A. Ribeiro, Shell Li, Sebastiao Cabral Filho, Andre Augusto Junior Gemeinder de Moraes
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Purpose Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth
Autor:
Brigitte M. Van Eyll, Fábio A. Franke, J.G.M. Segalla, Nills G. Skare, Otávio Gampel, Mirian Hatsue Honda Federico, Urias de Paula Filho, Ronaldo A. Ribeiro, Sebastião Cabral, Martha R. Perdicaris
Publikováno v:
Clinical colorectal cancer. 7(2)
Purpose This study evaluated the effects of oral capecitabine on the quality of life (QOL) of Brazilian patients with metastatic colorectal cancer who received capecitabine (1000 or 1250 mg/m2 twice a day on days 1-14, every 3 weeks) in a prospective
Autor:
Manuel Ruiz-Borrego, A. Ruiz, Roberto Torres, J. Bines, J.G.M. Segalla, L. Torrecillas, M. Martin, José A. García-Sáenz, Carlos Barrios, A. Lluch
Publikováno v:
European Journal of Cancer. 48:S169-S170
Autor:
M.N. Álvares, Gustavo Girotto, Carlos J C Andrade, Nicolas Lazaretti, B. Franca, H. Fernandes, Nils Gunnar Skare, D. Grabarz, J.G.M. Segalla, J.L. Pedrini, J.N.D. Matos Neto, L.P.D.G. Neusquen, Giuliano Santos Borges, C. Kussumoto, G. De Castro, A. Del Giglio, I. Dale, Nora Manoukian Forones, Sergio J Azevedo
Publikováno v:
Annals of Oncology. 25:iv218
Aim: NICE trial showed that combination of chemoradiation and nimotuzumab, a humanized antibody against EGFR, is safe and appears to increase the combined complete response (cCR) rate, defined as endoscopic and/or pathologic CR, in pts with locally a
Autor:
Sergio Vicente Serrano, Carlos H. Barrios, Rafael Schmerling, José Augusto Rinck, Antonio C. Buzaid, J.G.M. Segalla, Sergio J Azevedo, Vanessa Dybal Bertoni, Daniel Herchenhorn, Veridiana Pires de Camargo, Johnny Camargo
Publikováno v:
Journal of Clinical Oncology. 32:e20045-e20045
e20045 Background: Expanded Access Programs (EAP) for ipilimumab (IPI) were established around the world in order to provide appropriate drug access. This abstract reports the experience with IPI i...
Autor:
Gilberto de Castro, Fauze Maluf Filho, Nils Gunnar Skare, Ismael Dale Cotrim Guerreiro da Silva, Sergio J Azevedo, Cassiano Ricardo de Oliveira Berto, J.G.M. Segalla, Carlos J C Andrade, Lucienne Pereira Del Grossi Neusquen
Publikováno v:
Journal of Clinical Oncology. 32:4078-4078
4078 Background: Chemoradiation is the standard therapy for patients (pts) with inoperable LAEC. We sought to assess the safety and activity of chemoradiation combined with nimotuzumab, a humanized...